See more : Taiwan Allied Container Terminal Corp. (5601.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Dicerna Pharmaceuticals, Inc. (DRNA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dicerna Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- New World Development Company Limited (NWWDF) Income Statement Analysis – Financial Results
- Fujian Boss Software Corp. (300525.SZ) Income Statement Analysis – Financial Results
- Tuas Limited (TUALF) Income Statement Analysis – Financial Results
- Bergman & Beving AB (publ) (BERG-B.ST) Income Statement Analysis – Financial Results
- Bonava AB (publ) (BONAV-B.ST) Income Statement Analysis – Financial Results
Dicerna Pharmaceuticals, Inc. (DRNA)
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 164.31M | 23.90M | 6.18M | 2.28M | 295.00K | 184.00K | 0.00 | 0.00 | 7.02M | 7.91M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 205.38M | 109.34M | 45.71M | 36.98M | 41.69M | 43.97M | 29.45M | 11.56M | 11.57M | 10.71M |
| General & Administrative | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 72.13M | 42.75M | 21.69M | 25.88M | 18.35M | 19.24M | 15.65M | 5.82M | 4.70M | 4.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Cost & Expenses | 277.52M | 152.09M | 67.40M | 62.86M | 60.04M | 63.21M | 45.10M | 17.38M | 16.27M | 15.52M |
| Interest Income | 6.01M | 7.54M | 2.10M | 539.00K | 235.00K | 188.00K | 63.00K | 4.00K | 2.00K | 3.00K |
| Interest Expense | 20.00K | 3.00K | 603.00K | 0.00 | 0.00 | 0.00 | 199.00K | 952.00K | 1.34M | 997.00K |
| Depreciation & Amortization | 2.22M | 1.25M | 774.00K | 778.00K | 840.00K | 727.00K | 848.00K | 523.00K | 551.00K | 474.00K |
| EBITDA | -110.51M | -119.20M | -87.48M | -59.27M | -58.67M | -62.11M | -46.89M | -17.04M | -8.23M | -7.09M |
| EBITDA Ratio | -67.26% | -498.67% | -1,416.39% | -2,602.99% | -19,889.15% | -33,756.52% | 0.00% | 0.00% | -117.29% | -89.59% |
| Operating Income | -113.21M | -128.19M | -61.22M | -60.59M | -59.75M | -63.03M | -45.10M | -17.38M | -9.25M | -7.61M |
| Operating Income Ratio | -68.90% | -536.25% | -991.26% | -2,660.83% | -20,253.56% | -34,253.80% | 0.00% | 0.00% | -131.86% | -96.27% |
| Total Other Income/Expenses | 461.00K | 7.73M | -27.63M | 539.00K | 235.00K | 188.00K | -2.84M | -1.14M | -871.00K | -943.00K |
| Income Before Tax | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Income Before Tax Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| Income Tax Expense | 481.00K | 7.73M | -27.03M | 539.00K | 235.00K | 188.00K | -2.64M | -188.00K | 471.00K | 54.00K |
| Net Income | -112.75M | -120.46M | -88.85M | -60.05M | -59.51M | -62.84M | -47.94M | -18.52M | -10.12M | -8.56M |
| Net Income Ratio | -68.62% | -503.93% | -1,438.68% | -2,637.15% | -20,173.90% | -34,151.63% | 0.00% | 0.00% | -144.28% | -108.19% |
| EPS | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| EPS Diluted | -1.51 | -1.76 | -1.60 | -2.90 | -2.87 | -3.09 | -2.98 | -1.11 | -4.95 | -0.11 |
| Weighted Avg Shares Out | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
| Weighted Avg Shares Out (Dil) | 74.52M | 68.43M | 55.62M | 20.72M | 20.72M | 20.32M | 16.07M | 16.63M | 2.05M | 77.91M |
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion
SHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordisk
Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%
Source: https://incomestatements.info
Category: Stock Reports